$CAMX (-1,27 %)
$GUBRA (+2,11 %)
Ladies and gentlemen, I remain invested in Camurus.
The two Scandinavian biotech companies Camurus and Gubra are pooling their expertise. An exclusive cooperation and license agreement has been signed with the aim of developing a long-acting therapeutic option for the treatment of hypoparathyroidism, an underactive parathyroid gland.
This research and development program combines Gubra's parathyroid hormone (PTH) analog, developed using its proprietary peptide discovery platform "streaMLine", with Camurus' FluidCrystal technology to enable prolonged, patient-friendly dosing, according to a press release.
"Given the promising initial development data, we look forward to this collaboration combining Gubra's strengths in drug discovery and preclinical expertise with Camurus' technology, late-stage development capabilities and commercialization expertise," said Markus Johnsson, Senior Vice President R&D at Camurus.
Under the terms of the agreement, Camurus will develop and commercialize the product, while Gubra has the option to co-finance the development of the product. Gubra will in turn receive staggered license fees based on the level of financial participation.
CONCLUSION
Gubra has partnered another asset from its development pipeline at a relatively early stage. This clearly speaks for the Danes' strong expertise in drug discovery. With Camurus, the company has gained an excellent partner from Lund, Sweden, which also has a highly interesting technology platform to offer. Both stocks continue to be excellent long-term portfolio additions for speculative investors.
